Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cystadenocarcinoma, Serous"" wg kryterium: Temat


Tytuł:
Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
Autorzy:
Reavis HD; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.; Cell and Molecular Biology Graduate Group; and.; Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Gysler SM; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
McKenney GB; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
Knarr M; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
Lusk HJ; Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California, USA.
Rawat P; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
Rendulich HS; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
Mitchell MA; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.
Berger DS; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Moon JS; Department of Translational Molecular Medicine and Sequencing Center, Saint John's Cancer Institute, Providence Health Services, Santa Monica, California, USA.
Ryu S; Department of Translational Molecular Medicine and Sequencing Center, Saint John's Cancer Institute, Providence Health Services, Santa Monica, California, USA.
Mainigi M; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Iwanicki MP; Departments of Bioengineering, Chemistry, and Chemical Biology and Biological Sciences, Stevens Institute of Technology, Hoboken, New Jersey, USA.
Hoon DS; Department of Translational Molecular Medicine and Sequencing Center, Saint John's Cancer Institute, Providence Health Services, Santa Monica, California, USA.
Sanchez LM; Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California, USA.
Drapkin R; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology.; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
JCI insight [JCI Insight] 2024 Mar 08; Vol. 9 (5). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/metabolism
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/metabolism
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Fallopian Tubes/metabolism ; Fallopian Tubes/pathology ; Anoikis ; Norepinephrine/pharmacology ; Norepinephrine/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
Autorzy:
Petiot F; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France. Electronic address: .
Descargues P; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France.
Devouassoux-Shisheboran M; Université Lyon 1, CHU Lyon Sud, Department of Anatomopathology, Pierre Bénite, France.
You B; Université Lyon 1, CHU Lyon Sud, Department of Medical Oncology, Pierre Bénite, France.
Rousset-Jablonski C; INSERM U1290 RESearch on HealthcAre PErformance (RESHAPE), Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.
Raffin D; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France.
Hajri T; French Trophoblastic Disease Reference Center, CHU Lyon Sud, Pierre Bénite, France.
Gertych W; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France.
Glehen O; Université Lyon 1, CHU Lyon Sud, Department of Digestive Surgery, Pierre Bénite, France.
Philip CA; Université Lyon 1, CHU Croix-Rousse, Department of Obstetrics and Gynecology, Lyon, France.
Lamblin G; Université Lyon 1, Hôpital Femme Mère Enfant, Department of Obstetrics and Gynecology, Bron, France.
Golfier F; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France.
Bolze PA; Université Lyon 1, CHU Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France.
Pokaż więcej
Źródło:
European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2024 Mar; Vol. 294, pp. 191-197. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Ovarian Neoplasms*/surgery
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/surgery
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Retrospective Studies ; Carcinoma, Ovarian Epithelial/pathology ; Uterus/surgery ; Uterus/pathology ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Autorzy:
Dos Santos MV; Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310, Montebello, Oslo, Norway.; Permanent Address: Serviço de Anatomia Patológica, Centro Hospitalar Universitário de Lisboa Central E.P.E, Rua José António Serrano, 1150-199, Lisbon, Portugal.
Holth A; Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310, Montebello, Oslo, Norway.
Bischof K; Department of Gynecologic Oncology, Oslo University Hospital, Norwegian Radium Hospital, N-0310, Oslo, Norway.
Davidson B; Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310, Montebello, Oslo, Norway. .; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, N-0316, Oslo, Norway. .
Pokaż więcej
Źródło:
Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Feb; Vol. 41 (1), pp. 69-76. Date of Electronic Publication: 2023 Dec 23.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma*
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/metabolism
Cystadenocarcinoma, Serous*/pathology
Mesothelioma*/drug therapy
Mesothelioma*/pathology
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/surgery
Female ; Humans ; Biomarkers, Tumor ; Drug Resistance, Neoplasm ; Occludin/genetics ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Autorzy:
Nersesian S; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Arseneau RJ; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Mejia JP; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Lee SN; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Westhaver LP; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Griffiths NW; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Grantham SR; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Meunier L; Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, QC, Canada.
Communal L; Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, QC, Canada.
Mukherjee A; Akoya Biosciences, Menlo Park, CA, United States.
Mes-Masson AM; Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, QC, Canada.; Department of Medicine, Université de Montréal, Montreal, QC, Canada.
Arnason T; Department of Pathology, Dalhousie University, Halifax, NS, Canada.; Department of Pathology & Laboratory Medicine, QEII Health Sciences Centre, Nova Scotia Health (Central Zone), Halifax, NS, Canada.
Nelson BH; Deeley Research Centre, British Columbia Cancer Research Institute, Victoria, BC, Canada.; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Boudreau JE; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Jan 22; Vol. 14, pp. 1307873. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; T-Lymphocytes/pathology ; Carcinoma, Ovarian Epithelial ; Killer Cells, Natural/pathology ; Macrophages/pathology
Czasopismo naukowe
Tytuł:
Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Autorzy:
Ronchi S; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Facchi S; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Di Lauro E; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Libera L; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Carnevali IW; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Zefiro F; Department of Obstetric and Gynecology, ASST Settelaghi, University of Insubria, 21100 Varese, Italy. Electronic address: .
Alexandrova E; Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'ScuolaMedicaSalernitana', University of Salerno, 84081 Baronissi, Italy. Electronic address: .
Rizzo F; Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'ScuolaMedicaSalernitana', University of Salerno, 84081 Baronissi, Italy; Genome Research Center for Health - CRGS, Campus of Medicine of the University of Salerno, 84081 Baronissi, SA, Italy. Electronic address: .
Sessa F; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Tibiletti MG; Unit of Pathology, Ospedale di Circolo, ASST SetteLaghi, Research Center for Familial and Hereditary Tumors, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. Electronic address: .
Pokaż więcej
Źródło:
Pathology, research and practice [Pathol Res Pract] 2024 Mar; Vol. 255, pp. 155183. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/pathology
Fallopian Tube Neoplasms*/genetics
Fallopian Tube Neoplasms*/metabolism
Fallopian Tube Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/pathology ; BRCA1 Protein/analysis ; Germ-Line Mutation ; Tumor Suppressor Protein p53/metabolism ; BRCA2 Protein/analysis ; Fallopian Tubes/chemistry ; Fallopian Tubes/metabolism ; Fallopian Tubes/pathology ; Mutation ; Carcinogenesis/pathology ; Germ Cells/pathology
Czasopismo naukowe
Tytuł:
Solitary precaval right renal artery and bilateral double ureter in a patient with high-grade serous ovarian cancer.
Autorzy:
Schröder R; Department of Obstetrics and Gynecology, University Medical Center Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Diener MK; Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.
Taran FA; Department of Obstetrics and Gynecology, University Medical Center Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. .
Pokaż więcej
Źródło:
Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2024 Mar; Vol. 309 (3), pp. 1107-1108. Date of Electronic Publication: 2023 Jun 10.
Typ publikacji:
Journal Article
MeSH Terms:
Ureter*/diagnostic imaging
Ovarian Neoplasms*/complications
Ovarian Neoplasms*/surgery
Cystadenocarcinoma, Serous*
Humans ; Female ; Renal Artery/diagnostic imaging
Czasopismo naukowe
Tytuł:
Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Autorzy:
Murawski M; 1st Clinical Department of Gynecology and Obstetrics, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Jagodziński A; 1st Clinical Department of Gynecology and Obstetrics, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Bielawska-Pohl A; Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Klimczak A; Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Feb 15; Vol. 13 (4). Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/genetics
Female ; Humans ; BRCA1 Protein/genetics ; Tumor Suppressor Protein p53/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; BRCA2 Protein/genetics ; Carcinogenesis ; Cell Transformation, Neoplastic ; Class I Phosphatidylinositol 3-Kinases/genetics ; Genetic Background
Czasopismo naukowe
Tytuł:
Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Autorzy:
Wenk D; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Khan S; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Ignatchenko V; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
May T; Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto M5G 2C4, Ontario, Canada.; Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward Street, Toronto M5G 1E2, Ontario, Canada.
Bernardini MQ; Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto M5G 2C4, Ontario, Canada.; Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward Street, Toronto M5G 1E2, Ontario, Canada.
Kislinger T; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Pokaż więcej
Źródło:
Journal of proteome research [J Proteome Res] 2024 Feb 02; Vol. 23 (2), pp. 749-759. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/metabolism
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Biomarkers, Tumor ; Neoplasm Recurrence, Local ; Glycoproteins ; Mass Spectrometry ; Fibrinogen ; Latent TGF-beta Binding Proteins
Czasopismo naukowe
Tytuł:
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
Autorzy:
AlSomairi A; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Himayda S; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Altelmesani A; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Lee YJ; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. Electronic address: .
Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2024 Feb; Vol. 181, pp. 155-161. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/drug therapy
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/surgery
Ovarian Neoplasms*/pathology
Female ; Humans ; Artificial Intelligence ; CA-125 Antigen ; Carcinoma, Ovarian Epithelial/surgery ; Carcinoma, Ovarian Epithelial/drug therapy ; Chemotherapy, Adjuvant ; Cytoreduction Surgical Procedures ; Neoadjuvant Therapy ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Assessment of oncological safety and utility of hysteroscopy in high grade endometrial cancers: Results from an Israel gynecologic oncology group study.
Autorzy:
Namazov A; Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel. Electronic address: .
Helpman L; Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel.
Eitan R; Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel.
Vaknin Z; The Yitzhak Shamir Center (Formerly Assaf Harofeh Medical Center), Sackler School of Medicine, Tel Aviv University, Zerifin 70300, Israel.
Lavie O; Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Amit A; Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Levy T; Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Holon, Israel.
Shachar IB; Ziv Medical Center, Bar Ilan University, Zefat, Israel.
Atlas I; Poriya Medical Center, Bar Ilan University, Tiberia, Israel.
Bruchim I; Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hedera, Israel.
Arie AB; Kaplan Medical Center, Hebrew University, Rehovot, Israel.
Gemer O; Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel.
Pokaż więcej
Źródło:
European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2024 Feb; Vol. 293, pp. 67-71. Date of Electronic Publication: 2023 Dec 17.
Typ publikacji:
Journal Article
MeSH Terms:
Endometrial Neoplasms*/diagnosis
Endometrial Neoplasms*/surgery
Endometrial Neoplasms*/pathology
Uterine Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Pregnancy ; Female ; Humans ; Hysteroscopy ; Israel ; Endometrium/pathology
Czasopismo naukowe
Tytuł:
[Antitumor effects of redox-responsive nanoparticles containing platinum(Ⅳ)in ovarian cancer].
Autorzy:
Hou HY; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Tang DS; Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Zhang YN; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang KY; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ao M; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Luo HX; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li B; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jan 23; Vol. 46 (1), pp. 76-85.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Cystadenocarcinoma, Serous*
Humans ; Female ; Animals ; Mice ; Platinum ; Cisplatin/pharmacology ; Cell Line, Tumor ; Ki-67 Antigen ; Carcinoma, Ovarian Epithelial ; Disease Models, Animal ; Eosine Yellowish-(YS) ; Necrosis ; Polymers ; Body Weight
Czasopismo naukowe
Tytuł:
The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases.
Autorzy:
You X; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Dong Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Wang J; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Cheng Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Jia Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Zhang X; Department of Pathology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Wang J; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 17; Vol. 24 (1), pp. 99. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Uterine Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Recurrence ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Autorzy:
Li YK; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Gao AB; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; Clinical Research Institute, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zeng T; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Liu D; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Zhang QF; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Ran XM; Department of Gynecologic Oncology, School of Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya, Central South University, Changsha, Hunan, China.
Tang ZZ; Department of Gynecologic Oncology, School of Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya, Central South University, Changsha, Hunan, China.
Li Y; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Liu J; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhang T; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Shi GQ; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhou WC; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zou WD; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Peng J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Zhang J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. .
Li H; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. lihui_.
Zou J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. .; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Jan 11; Vol. 22 (1), pp. 46. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*
Ovarian Neoplasms*/genetics
STAT3 Transcription Factor*
Janus Kinase 2*
Animals ; Female ; Humans ; Tumor Microenvironment ; Molecular Docking Simulation ; Angiogenesis ; Zebrafish/metabolism ; Carcinogenesis ; Cell Proliferation ; Carcinoma, Ovarian Epithelial ; Cell Line, Tumor ; Angiopoietin-Like Protein 4/genetics ; Neoplasm Proteins ; Proteoglycans
Czasopismo naukowe
Tytuł:
Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
Autorzy:
Dai Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Xu J; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Gong X; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Wei J; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Gao Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Chai R; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Lu C; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Zhao B; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Kang Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 10; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/genetics
Ovarian Neoplasms*/genetics
Humans ; Female ; Fallopian Tubes ; Carcinoma, Ovarian Epithelial ; Mutation ; Tumor Suppressor Protein p53/genetics ; DNA-Binding Proteins
Czasopismo naukowe
Tytuł:
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
Autorzy:
Karakas C; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Giampoli EJ; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Love T; Department of Biostatistics and Computation Biology, University of Rochester, Rochester, NY, USA.
Hicks DG; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Velez MJ; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. Moises_.
Pokaż więcej
Źródło:
Diagnostic pathology [Diagn Pathol] 2024 Jan 10; Vol. 19 (1), pp. 10. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma*
Cystadenocarcinoma, Serous*
Humans ; Cytoplasm ; Immunohistochemistry ; Introns ; Receptor Protein-Tyrosine Kinases
Czasopismo naukowe
Tytuł:
Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix.
Autorzy:
Kommoss FK; Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Lee CH; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Tessier-Cloutier B; Department of Pathology, McGill University, Montreal, QC, Canada.
Gilks CB; Department of Laboratory Medicine and Pathology, University of British Columbia, Vancouver, BC, Canada.
Stewart CJ; Department of Anatomical Pathology, King Edward Memorial Hospital, Subiaco, WA, Australia.; School for Women's and Infants' Health, University of Western Australia, Perth, WA, Australia.
von Deimling A; Department of Neuropathology, Heidelberg University Hospital and CCU Neuropathology DKFZ, Heidelberg, Germany.
Köbel M; Department of Laboratory Medicine and Pathology, University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Źródło:
The Journal of pathology [J Pathol] 2024 Jan; Vol. 262 (1), pp. 4-9. Date of Electronic Publication: 2023 Oct 18.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Endometrioid*/genetics
Carcinoma, Endometrioid*/pathology
Cystadenocarcinoma, Serous*/genetics
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Female ; Humans ; Cervix Uteri/pathology ; DNA Copy Number Variations ; DNA Methylation ; Carcinoma, Ovarian Epithelial/genetics
Czasopismo naukowe
Tytuł:
Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma.
Autorzy:
Kilic F; Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Ersak B; Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Cakir C; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Yuksel D; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Kilic C; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Korkmaz V; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Tokgozoglu N; Department of Gynecologic Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Toptas T; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Boran N; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Kimyon Comert G; Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Ureyen I; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Tasci T; Department of Gynecologic Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Moraloglu Tekin O; Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Ustun Y; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Turan T; Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Pokaż więcej
Źródło:
The journal of obstetrics and gynaecology research [J Obstet Gynaecol Res] 2024 Jan; Vol. 50 (1), pp. 86-94. Date of Electronic Publication: 2023 Oct 19.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Uterine Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Carcinoma*
Ovarian Neoplasms*/pathology
Female ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł:
P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Autorzy:
Bates M; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland. Electronic address: .
Mullen D; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Lee E; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Costigan D; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Heron EA; Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland.
Kernan N; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Barry-O'Crowley J; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Martin C; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Keegan H; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Malone V; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Brooks RD; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Brooks DA; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Logan JM; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Martini C; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Selemidis S; Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology, Bundoora, Australia.
McFadden J; Department of Histopathology, St James's Hospital, Dublin, Ireland.
O'Riain C; Department of Histopathology, St James's Hospital, Dublin, Ireland.
Spillane CD; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland.
Gallagher MF; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland.
McCann A; UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin and UCD School of Medicine, University College Dublin, UCD, Belfield Dublin 4, Ireland.
O'Toole S; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland.
O'Leary JJ; Department of Histopathology, Trinity College Dublin, Dublin, Ireland; Emer Casey Molecular Pathology Research Laboratory, Coombe Women & Infants University Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, Dublin, Ireland; Department of Pathology, Coombe Women & Infants University Hospital, Dublin, Ireland.
Pokaż więcej
Źródło:
Pathology, research and practice [Pathol Res Pract] 2024 Jan; Vol. 253, pp. 155020. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/metabolism
Ovarian Neoplasms*/metabolism
Female ; Humans ; Biomarkers ; Biomarkers, Tumor/metabolism ; Carcinoma, Ovarian Epithelial ; Prognosis ; Progression-Free Survival ; Toll-Like Receptor 4/metabolism ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł:
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Autorzy:
Koskela H; Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.
Li Y; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Joutsiniemi T; Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.
Muranen T; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Isoviita VM; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Huhtinen K; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Institute of Biomedicine and FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
Micoli G; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Lavikka K; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Marchi G; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Hietanen S; Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.
Virtanen A; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Hautaniemi S; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Oikkonen J; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Hynninen J; Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2024 Jan; Vol. 180, pp. 91-98. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Clinical Trial; Journal Article; Observational Study
MeSH Terms:
Cystadenocarcinoma, Serous*/pathology
Ovarian Neoplasms*/pathology
Female ; Humans ; Cicatrix/pathology ; Prognosis ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
Autorzy:
Wang X; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Molecular Pathology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Sun J; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Liu Y; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Lin Z; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Jiang X; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Ye Y; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Lv C; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Lian X; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Xu W; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Luo S; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Liao S; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Chen Z; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Wang S; Key Laboratory of Stem Cell Engineering and Regenerative Medicine of Fujian Province University, Fujian Medical University, Fuzhou, China.; Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Pokaż więcej
Źródło:
International journal of cancer [Int J Cancer] 2024 May 01; Vol. 154 (9), pp. 1639-1651. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/pathology
Ovarian Neoplasms*/pathology
Male ; Female ; Humans ; Transcription Factors/genetics ; Prognosis ; Cell Proliferation ; Repressor Proteins/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies